Regeneron Pharmaceuticals Attend July 22th Obesity Drug Development Summit http://www
Regeneron Pharmaceuticals Attend July 22th Obesity Drug Development Summit http://www.cbinet.com/show_conferenc...9&field=daytwo
In Vivo Target Discovery and Validation by High Throughput Genome Engineering
A high throughput genome engineering technology platform has been developed to determined the in vivoexpression pattern of many novel obesity and diabetes-related genes at high resolution, validate and invalidate putative targets as well as dissected important metabolic pathways. This method also provides important insights into mechanisms of novel compounds currently in development for the treatment of obesity and diabetes.
Overview of technology
Validation and invalidation of diabesity targets using KO models
SHIP2 lipid phosphatase as target for treatment of obesity
Mark W. Sleeman, Ph.D., Director of Neural and Endocrine Biology,Regeneron Pharmaceuticals Inc.
Watch REGN these days, getting hotter and hotter. Valueline raise its timeliness on June based on REGN's much-better-than-before financial statement and its new drugs research with its target $15. Three years target from Valueline is $25.
Regeneron Pharmaceuticals Attend July 22th Obesity Drug Development Summit http://www.cbinet.com/show_conferenc...9&field=daytwo
In Vivo Target Discovery and Validation by High Throughput Genome Engineering
A high throughput genome engineering technology platform has been developed to determined the in vivoexpression pattern of many novel obesity and diabetes-related genes at high resolution, validate and invalidate putative targets as well as dissected important metabolic pathways. This method also provides important insights into mechanisms of novel compounds currently in development for the treatment of obesity and diabetes.
Overview of technology
Validation and invalidation of diabesity targets using KO models
SHIP2 lipid phosphatase as target for treatment of obesity
Mark W. Sleeman, Ph.D., Director of Neural and Endocrine Biology,Regeneron Pharmaceuticals Inc.
Watch REGN these days, getting hotter and hotter. Valueline raise its timeliness on June based on REGN's much-better-than-before financial statement and its new drugs research with its target $15. Three years target from Valueline is $25.
Comment